Trigg Minerals (ASX: TMG) managing director Keren Paterson joins Small Caps to discuss the company’s progress at its Lake Throssell sulphate of potash (SOP) project in Western Australia.

Recent assays from drilling have confirmed the consistency and robustness of the deposit, with a resource upgrade expected later this month.

Ms Paterson says all data is feeding into a pre-feasibility study and maiden ore reserve for the project.

Articles:
https://smallcaps.com.au/trigg-minerals-reveals-brine-grades-ahead-lake-throssell-sop-resource-upgrade/

For more information on Trigg Minerals:
https://smallcaps.com.au/stocks/TMG/

Trigg Minerals (ASX: TMG) managing director Keren Paterson joins Small Caps to discuss the company’s progress at its Lake Throssell sulphate of potash (SOP) project in Western Australia.
Recent assays from drilling have confirmed the consistency and robustness of the deposit, with a resource upgrade expected later this month.
Ms Paterson says all data is feeding into a pre-feasibility study and maiden ore reserve for the project.
Articles: <a href="https://smallcaps.com.au/trigg-minerals-reveals-brine-grades-ahead-lake-throssell-sop-resource-upgrade/">https://smallcaps.com.au/trigg-minerals-reveals-brine-grades-ahead-lake-throssell-sop-resource-upgrade/</a>
For more information on Trigg Minerals: <a href="https://smallcaps.com.au/stocks/TMG/">https://smallcaps.com.au/stocks/TMG/</a>

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

Small Caps is Australia's #1 site for investor news &amp; information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of ASX listed small cap companies and financial market analysts.

Small Caps

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies.

The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts.

For more information visit: https://smallcaps.com.au/

Trigg Minerals (ASX: TMG) closes-in on resource upgrade for Lake Throssell sulphate of potash project (w/ Keren Paterson)

Gerald Celente, founder of the Trends Research Institute and Trends Journal magazine, joins Small Caps to discuss the current events that are forming future trends.

With a 40-year track record of identifying, tracking and forecasting trends, Gerald is renowned as the world's #1 trend forecaster.

Topics discussed include: WW3, gold and silver, the office building bust and banks, the levels of debt, AI and much more..

Gerald Celente, founder of the Trends Research Institute and Trends Journal magazine, joins Small Caps to discuss the current events that are forming future trends.
With a 40-year track record of identifying, tracking and forecasting trends, Gerald is renowned as the world's #1 trend forecaster.
Topics discussed include: WW3, gold and silver, the office building bust and banks, the levels of debt, AI and much more..

Gerald Celente: World War 3 has begun, gold headed to $3,000

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).

The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.

Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .

Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.

It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.

While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.

April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.

Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.

Articles:
https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/
https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/

For more information on Anatara Lifesciences:
https://smallcaps.com.au/stocks/asx-anr/

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).
The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.
Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .
Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.
It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.
While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.
April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.
Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.
Articles: <a href="https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/">https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/</a> <a href="https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/">https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/</a>
For more information on Anatara Lifesciences: <a href="https://smallcaps.com.au/stocks/asx-anr/">https://smallcaps.com.au/stocks/asx-anr/</a>

Anatara Lifesciences (ASX: ANR) reaches milestone in progression of Phase II IBS trial (w/ David Brookes)

Barry Dawes, executive chairman at Martin Place Securities, join Small Caps to share his views on the recent rise in gold and silver prices.

Other topics discussed include various commodities such as copper, iron ore and uranium.
Discussion on currencies such as the US dollar, Japanese yen and Australian dollar.
And some ASX stocks.

To find out about investment opportunities in IPOs and placements visit Cap Raise:
https://capraise.com/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/

Barry Dawes, executive chairman at Martin Place Securities, join Small Caps to share his views on the recent rise in gold and silver prices.
Other topics discussed include various commodities such as copper, iron ore and uranium. Discussion on currencies such as the US dollar, Japanese yen and Australian dollar. And some ASX stocks.
To find out about investment opportunities in IPOs and placements visit Cap Raise: https://capraise.com/
-----------------------
Small Caps is Australia's #1 site for market news &amp; information on ASX listed small cap companies.
-----------------------
WEBSITE https://smallcaps.com.au/
PODCAST https://smallcaps.com.au/podcast/
SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/
NEWSLETTER https://smallcaps.com.au/subscribe/

Trigg Minerals (ASX: TMG) closes-in on resource upgrade for Lake Throssell sulphate of potash project (w/ Keren Paterson)

In 1 playlist(s)

Small Caps

Social links

Follow podcast

Recent clips